Equipe de Recherche sur la Biochimie et la Pharmacologie des Vaisseaux et du Rein", Laboratoire de Pharmacologie, Faculté de Pharmacie, Université de Paris V & VI, France; Laboratoire de Biochimie, Hôpital Bichat, Paris, France.
Equipe de Recherche sur la Biochimie et la Pharmacologie des Vaisseaux et du Rein", Laboratoire de Pharmacologie, Faculté de Pharmacie, Université de Paris V & VI, France.
Diabetes Res Clin Pract. 2014 Sep;105(3):373-81. doi: 10.1016/j.diabres.2014.04.029. Epub 2014 May 9.
Advanced glycation endproducts (AGEs) have been shown to contribute to alteration of glomerular permselectivity to proteins in diabetes. Oxidative stress is required for AGE formation. Therefore we studied the effect of an antioxidant micronized purified flavonoid fraction (MPFF, Daflon(R) 500 mg), on urinary albumin clearance in diabetic rats.
Hyperglycaemia was induced by streptozotocin 55 mg/kg IM at days 0 and 7 in normotensive Wistar rats (NWR, diabetes duration 5 months) or hypertensive Wistar Kyoto rats (SHR, diabetes duration 2 months). MPFF was administered at 300 mg/kg/day, from day -2 until sacrifice.
After 5 months of diabetes in NWR, MPFF reduced albumin clearance from 729±92 to 392±60 nl/min/kg, p<0.01, and restored albuminemia from 20.4±0.9 to 24.0±1 g/l, p<0.05; albumin fractional clearance was significantly diminished in the flavonoid-treated diabetic rats (0.360±0.037‰ versus 1.335±0.430‰ in the diabetic controls, p<0.001); MPFF did not significantly modify blood glucose and plasma fructosamine levels. After 2 months of diabetes in SHR, MPFF reduced albumin clearance from 243±121 to 101±47 nl/min/kg, p<0.05, and restored albuminemia from 21.1±1.6 to 26.7±2.2 g/l (p<0.05); MPFF also decreased plasma fluorescence characteristic of AGEs (p<0.02). Besides hesperetin, a main metabolite of MPFF recovered in plasma, inhibited in vitro the formation of the crosslinking AGE pentosidine in collagen incubated with high glucose (p<0.001).
Our results confirm the role of glycoxidative stress in diabetic nephropathy. MPFF might be useful as complementary treatment for preventing diabetic microangiopathy.
已有研究表明,糖基化终产物(AGEs)可导致糖尿病患者肾小球对蛋白质的滤过选择性发生改变。氧化应激是 AGE 形成的必要条件。因此,我们研究了抗氧化剂米诺地尔纯化黄酮类化合物(MPFF,Daflon(R)500mg)对糖尿病大鼠尿白蛋白清除率的影响。
正常血压 Wistar 大鼠(NWR,糖尿病病程 5 个月)或高血压 Wistar 京都大鼠(SHR,糖尿病病程 2 个月)于第 0 天及第 7 天经腹腔注射链脲佐菌素 55mg/kg 诱导高血糖。从第-2 天至处死,MPFF 给药剂量为 300mg/kg/天。
在 NWR 糖尿病病程 5 个月后,MPFF 将白蛋白清除率从 729±92 降至 392±60 nl/min/kg,p<0.01,并将白蛋白血症从 20.4±0.9 恢复至 24.0±1g/l,p<0.05;在接受黄酮类化合物治疗的糖尿病大鼠中,白蛋白分数清除率显著降低(0.360±0.037‰与糖尿病对照组的 1.335±0.430‰相比,p<0.001);MPFF 对血糖和血浆果糖胺水平无显著影响。在 SHR 糖尿病病程 2 个月后,MPFF 将白蛋白清除率从 243±121 降至 101±47 nl/min/kg,p<0.05,并将白蛋白血症从 21.1±1.6 恢复至 26.7±2.2g/l(p<0.05);MPFF 还降低了血浆中 AGE 特征荧光(p<0.02)。除了在血浆中回收的主要代谢物橙皮素外,MPFF 还抑制了在高糖孵育下胶原蛋白中交联 AGE 戊糖的形成(p<0.001)。
我们的研究结果证实了糖基化氧化应激在糖尿病肾病中的作用。MPFF 可能是预防糖尿病微血管病变的辅助治疗方法。